Supportive therapy for dysmenorrhea: Time to look beyond mefenamic acid in primary care

Gomathy, Nachimuthu; Dhanasekar, Karukkupalayam Ramasamy; Dutta, Trayambak; Amirtha, Rajasekar

doi:10.4103/jfmpc.jfmpc_717_19

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of MFA and NSAIDS aim to reduce pain rather than alter pain sensitivity and other neuronal symptoms of dysmenorrhea [17]. Due to their anti-inflammatory action, NSAIDS have been investigated as an adjunct to assisted reproduction technology; however, there is no clear evidence that they provide any benefit [18].…”

Section: Management Optionsmentioning

confidence: 99%

Nonsurgical management of adenomyosis: an overview of current evidence

Lazaridis

Grammatis

Spencer

et al. 2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewAdenomyosis is a condition where endometrium-like tissue spreads within the myometrium. Although its prevalence in the general population is not exactly known, its clinical manifestations are well established and include pelvic pain, dysmenorrhea (painful periods), heavy menstrual bleeding and subfertility [1]. Adenomyosis often coexists with other gynaecological conditions, such as endometriosis or fibroids, and may cloud the clinical presentation [2]. The aim of this article is to review current noninterventional, nonsurgical management modalities and wherever possible offer information that allows women to make safe and informed choices regarding their treatment options. Recent findingsRecent studies support that medical strategies, including the Mirena coil, Dienogest and GnRH antagonists, are efficient in improving adenomyosis-associated symptoms. High-quality evidence is scarce and is needed to properly counsel women with this condition. Future research should prioritize overall pain, menstrual bleeding, quality of life and live birth as primary outcomes and assess women with different grades of adenomyosis.

show abstract

Section: Management Optionsmentioning

confidence: 99%

Nonsurgical management of adenomyosis: an overview of current evidence

Lazaridis

Grammatis

Spencer

et al. 2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Cryotherapy Produces Pain Relief in Young People with Primary Dysmenorrhea

Silva

Canova

Bortoletto

et al. 2022

Therapeutic Hypothermia and Temperature Management

View full text Add to dashboard Cite

Primary dysmenorrhea is characterized as painful menstruation without associated pelvic disease and has been considered common among young people of reproductive age. Cryotherapy is a technique aimed at analgesia and anti-inflammatory action. The objective of this study was to analyze the analgesic efficacy of cryotherapy in sedentary youth with primary dysmenorrhea. Methods were included sedentary, affected by primary dysmenorrhea. The analysis of pain intensity by visual analog scale (VAS) and the Brazilian Version of the Wisconsin Brief Pain Questionnaire were used for evaluation. The participants were randomly separated into a control group (CG, n = 10) and a cryotherapy group (CryoG, n = 10). The evaluations and treatment occurred during a menstrual cycle, with three interventions, in the initial 3 days of higher menstrual flow history report. CG showed a reduction in pain when comparing the 1st with the 4th day of assessment; CryoG showed a daily reduction in VAS; for the pain questionnaire, cryotherapy showed a reduction in interference with sleep dysmenorrhea; and for all other variables, although there was no significant difference, a large effect size was observed. Cryotherapy was effective in reducing pain in women with primary dysmenorrhea, with indication of clinical improvement in daily living activities.

show abstract

New validated Reverse Phase Ultra Performance Liquid Chromatography method for drospirenone and estetrol in Active Pharmaceutical Ingredient and tablet form and its stress studies

Syed¹,

Rambabu²

2021

J Appl Pharm Sci

View full text Add to dashboard Cite

The UPLC technique we have developed is completely unique and reliable and can quantitatively measure drospirenone and estetrol (E4) simultaneously. The chromatographic column of Luna C18 (100 × 2.6 mm, 1.6 µ) and isocratic elution, with a buffer (0.1% formic acid) and acetonitrile (30:70 v/v), using a flow of 1 ml/minutes at room temperature was used. The process was monitored by ultraviolet detection at 262 nm. A total of 3 minutes was dedicated to using a 3-minute timer to separate drospirenone and E4. Within the concentration range from 3 to 45 µg/ml of drospirenone and 14.2-213 µg/ml of E4, the analysis was completed in less than 5 minutes. System suitability parameters were studied and the outcomes were within acceptable limits when they were injected with the standard six times. To confirm the safety of the formulated product, a market-bought solution was assayed and it was found to be within specification. With all conditions and the acceptable range allowed, degradation studies were carried out on drospirenone and E4, all of which came back with a purity threshold that was higher than the purity angle. This particular technique was found to be consistent with the guidelines set forth by the International Council on Harmonization.

show abstract

Supportive therapy for dysmenorrhea: Time to look beyond mefenamic acid in primary care

Cited by 4 publications

References 23 publications

Nonsurgical management of adenomyosis: an overview of current evidence

Nonsurgical management of adenomyosis: an overview of current evidence

Cryotherapy Produces Pain Relief in Young People with Primary Dysmenorrhea

New validated Reverse Phase Ultra Performance Liquid Chromatography method for drospirenone and estetrol in Active Pharmaceutical Ingredient and tablet form and its stress studies

Contact Info

Product

Resources

About